SOUTH SAN FRANCISCO, Calif. (AP) _ Rigel Pharmaceuticals Inc. (RIGL) on Wednesday reported a loss of $25.6 million in its second quarter.
On a per-share basis, the South San Francisco, California-based company said it had a loss of 16 cents.
The results met Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was also for a loss of 16 cents per share.
The drug developer posted revenue of $1.8 million in the period, beating Street forecasts. Three analysts surveyed by Zacks expected $303,000.
In the final minutes of trading on Wednesday, the company's shares hit $2.68. A year ago, they were trading at $2.25.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on RIGL at https://www.zacks.com/ap/RIGL